Roche Diagnostics Corp. v. Apex Biotechnology Corp.

455 F. Supp. 2d 840, 2005 U.S. Dist. LEXIS 24387, 2005 WL 2363068
District Court, S.D. Indiana·Decided September 26, 2005·No. 1:04 CV 00358 LJM VS, 1:04 CV 01187 LJM VS·Published·Cited by 2 cases

Opinion

ORDER ON CLAIM CONSTRUCTION

MCKINNEY, Chief Judge.

On August 1, 2005, the Court held a hearing to assist it with construction of the claim language of the patent at issue in this infringement suit, U.S. Patent No. 5,366,609 (the “’609 patent”). Guided by the Supreme Court’s opinion in Markman v. Westview Inst., Inc., 517 U.S. 370, 388-90, 116 S.Ct. 1384, 134 L.Ed.2d 577 (1996) (“Markman II”), and by the Federal Circuit’s opinions in Markman v. Westview Inst., Inc., 52 F.3d 967 (Fed.Cir.1995) (“Markman I”) and Phillips v. AWH Corp., 415 F.3d 1303 (Fed.Cir.2005), the claim construction rendered herein will not be a “tentative one” subject to change upon receipt of additional information and evidence, but a definitive one based on all of the evidence of record at this point in the litigation. See Int’l Comm. Mat’ls, Inc. v. Ricoh Co., Ltd., 108 F.3d 316, 318-19 (Fed.Cir.1997) (noting that district court performed a “tentative construction” of the claim language to facilitate a decision of the preliminary injunction issue). The parties in these suits, plaintiffs, Roche Diagnostics Corporation, Roche Diagnostics Operations, Inc., Roche Diagnostics GmbH, and Corange International, Ltd. (collectively, “Roche”), and defendants, Apex Biotechnology Corp., Hypoguard USA, Inc., Medline Industries, Inc., (collectively, “Apex Defendants”), Home Diagnostics, Inc. (“HDI”) (these defendants collectively, “Apex/HDI”), and Biosite Incorporated (“Biosite”) (all defendants collectively “Defendants”), have narrowed the terms in dispute in the only claim at issue, claim 1.

The Court notes that at the claim construction hearing, all the parties referenced certain aspects of the allegedly infringing devices. The Court will not use these references to construe the claims of the ’609 patent as to do so is improper. *846 See SRI Int’l v. Matsushita Elec. Corp. of Am., 775 F.2d 1107, 1118 (Fed.Cir.1985); see also Ferguson Beauregard/Logic Controls, Div. of Dover Res., Inc. v. Mega Sys., LLC, 350 F.3d 1327, 1340 (Fed.Cir.2003) (citing SRI International for the same proposition). In other words, the Court will ascertain what the claims include rather than what they exclude.

Having been fully advised by the parties of their relative positions, the Court sets forth the relevant legal rules and application of those rules to the patent in dispute.

I. CLAIM CONSTRUCTION STANDARDS

When construing the ’609 patent’s claims, the Court must determine the meaning of the language used before it can ascertain the scope of the claims Roche asserts are infringed. See Markman I, 52 F.3d at 979. In doing so, the Court’s interpretive focus is not the subjective intent of the parties employing a certain term, but the objective test of what one of ordinary skill in the art at the time of the invention would have understood the term to mean. See Phillips, 415 F.3d at 1313; Innova/Pure Water v. Safari Water Filtration, 381 F.3d 1111, 1116 (Fed.Cir. 2004). When the Court undertakes its duty to construe the claims, it first must look to the intrinsic evidence: the asserted and unasserted claims, the specification, and the prosecution history. See Phillips, 415 F.3d at 1314; Ecolab, Inc. v. Envirochem, Inc., 264 F.3d 1358, 1366 (Fed.Cir. 2001); Vitronics Corp. v. Conceptronic, Inc., 90 F.3d 1576, 1581 (Fed.Cir.1996); Markman I, 52 F.3d at 979. Most of the time, such evidence will provide sufficient information for construing the claims. See Vitronics, 90 F.3d at 1583.

The patent claims should “ ‘particularly point out and distinctly clai[m] the subject matter which the applicant regards as his invention.’ ” Markman II, 517 U.S. at 373, 116 S.Ct. 1384 (citing 35 U.S.C. § 112). During claim construction, the appropriate starting point for the Court’s inquiry is always the words of both the asserted and unasserted claims. See Phillips, 415 F.3d at 1314; Elkay Mfg. Co. v. Ebco Mfg. Co., 192 F.3d 973, 977 (Fed. Cir.1999); see also Renishaw PLC v. Marposs Societa’ per Azioni, 158 F.3d 1243, 1248 (Fed.Cir.1998). As the Federal Circuit has noted, “[c]ommon words, unless the context suggest otherwise, should be interpreted according to their ordinary meaning.” Desper Prods., 157 F.3d at 1336 (citing York Prods., Inc. v. Central Tractor Farm & Family Ctr., 99 F.3d 1568, 1572 (Fed.Cir.1996)). See also Phillips, 415 F.3d at 1314 (citing Brown v. 3M, 265 F.3d 1349, 1352 (Fed.Cir.2001)). Further, when there are several common meanings for a term, “the patent disclosure serves to point away from the improper meanings and toward the proper meaning.” Renishaw, 158 F.3d at 1250. Accord Phillips, 415 F.3d at 1315-17 (discussing the role of the specification in claim construction).

The correct claim construction is also the one that “stays true to the claim language and most naturally aligns with the patent’s description of the invention.” Renishaw, 158 F.3d at 1250. See also Phillips, 415 F.3d at 1316. That description, or specification, serves an important purpose. In it, the patentee must provide a written description of the invention that would allow a person of ordinary skill in the art to make and use the invention. See Phillips, 415 F.3d at 1313-14; Markman I, 52 F.3d at 979. The applicable statute requires that “[t]he specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any *847 person skilled in the art to which it pertains ... to make and use the same.... ” 35 U.S.C. § ¶ 112, ¶ 1. See also Phillips, 415 F.3d at 1312, 1315; Johnson Worldwide Assocs., 175 F.3d at 993. Therefore, to discover the correct meaning of a disputed claim term, the Court must refer to the specification’s description of the invention.

In addition, a patentee may be his or her own lexicographer and use terms in a manner different from their ordinary meaning. See Phillips, 415 F.3d at 1316; Johnson Worldwide Assocs., 175 F.3d at 990; Vitronics, 90 F.3d at 1582.

Free access — add to your briefcase to read the full text and ask questions with AI

Roche Diagnostics Corp. v. Apex Biotechnology Corp., 455 F. Supp. 2d 840, 2005 U.S. Dist. LEXIS 24387, 2005 WL 2363068 (S.D. Ind. 2005).

455 F. Supp. 2d 840 (Roche Diagnostics Corp. v. Apex Biotechnology Corp.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Stanacard, LLC v. Rebtel Networks, Ab
680 F. Supp. 2d 483 (S.D. New York, 2010)
Brown v. BAYLOR HEALTH CARE SYSTEM
662 F. Supp. 2d 669 (S.D. Texas, 2009)